Golimumab is as safe as other anti TNF medications
(dailyRx News) Clinicians are generally familiar with the side effects of most prescribed medications. However, the safety of newer medications such as golimumab, an anti-TNF drug to treat autoimmune disorders, is still being examined.
Rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis are all chronic autoimmune disorders that may require patients to take medications for extended periods of time. Therefore, studying the safety of these medications over long periods of administration is important.
Golimumab (Simponi), a newer medication of the anti-TNF type, was FDA approved in 2009. Anti-TNF medications inhibit the substances (TNF) responsible for inflammation.
This recent study assessed the adverse effects of golimumab in patients who have been using it for up to three years. The authors found that golimumab has similar long-term side effects as other anti-TNF drugs, but the study on the safety of golimumab will continue for another two years.
Read more from RxWiki HERE.